Low Grade Gastric Mucosa-associated Lymphoid Tissue Lymphoma: Clinicopathological Factors Associated with Helicobacter pylori Eradication and Tumor Regression
- PMID: 22741120
- PMCID: PMC3363061
- DOI: 10.5946/ce.2011.44.2.101
Low Grade Gastric Mucosa-associated Lymphoid Tissue Lymphoma: Clinicopathological Factors Associated with Helicobacter pylori Eradication and Tumor Regression
Abstract
Background/aims: Eradication of Helicobacter pylori is widely accepted as initial therapy for low-grade gastric mucosa-associated lymphoid tissue (MALT) lymphoma. However, approximately 20% of patients with this disease are not responsive to H. pylori eradication therapy. The aim of this study was to assess remission and relapse rates of low-grade gastric MALT lymphoma after H. pylori eradication and identify the clinical factors that affect remission.
Methods: Thirty-nine patients diagnosed with gastric MALT lymphoma (May 2003 to May 2010) were retrospectively analyzed.
Results: Of the 39 patients, 30 (77%) had a H. pylori infection. There were 35/39 (90%) patients with stage I. Among stage I, 25 patients with the infection underwent eradication therapy and 22/25 (88%) achieved remission. The total regression rate with eradication only in stage I was 24/28 (86%). The median time to remission was 98 days (range, 22 to 397 days). Age, tumor location, invasion depth, H. pylori burden, and severity of mononuclear leukocyte and neutrophil infiltration were not related to remission. However, patients with less neutrophil infiltration were more likely to achieve a successful first H. pylori eradication (p=0.049).
Conclusions: The results show that the rate of low-grade gastric MALT lymphoma regression (86%) with H. pylori eradication alone was higher than that in Western studies (77.8%) and that neutrophil infiltration was inversely related to success of the first H. pylori eradication procedure.
Keywords: Eradication; Helicobacter pylori; Lymphoma; Mucosa-associated lymphoid tissue; Remission.
Conflict of interest statement
The authors have no financial conflicts of interest.
Figures



Similar articles
-
[Helicobacter pylori eradication for stage I(E₁) gastric mucosa-associated lymphoid tissue lymphoma: predictive factors of complete remission].Korean J Gastroenterol. 2010 Feb;55(2):94-9. doi: 10.4166/kjg.2010.55.2.94. Korean J Gastroenterol. 2010. PMID: 20168055 Korean.
-
Malignant tumors of the stomach. Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori.Gastroenterol Clin North Am. 2000 Sep;29(3):593-607. doi: 10.1016/s0889-8553(05)70132-1. Gastroenterol Clin North Am. 2000. PMID: 11030075 Review.
-
Treatment of low grade gastric mucosa-associated lymphoid tissue lymphoma in stage I with Helicobacter pylori eradication. Long-term results after sequential histologic and molecular follow-up.Haematologica. 2001 Jun;86(6):609-17. Haematologica. 2001. PMID: 11418369 Clinical Trial.
-
Regression of gastric high grade mucosa associated lymphoid tissue (MALT) lymphoma after Helicobacter pylori eradication.Gut. 2001 Oct;49(4):584-7. doi: 10.1136/gut.49.4.584. Gut. 2001. PMID: 11559658 Free PMC article. Review.
-
[Prognostic impact of Helicobacter pylori infection and eradication therapy in gastric mucosa-associated lymphoid tissue lymphoma].Korean J Lab Med. 2010 Dec;30(6):547-53. doi: 10.3343/kjlm.2010.30.6.547. Korean J Lab Med. 2010. PMID: 21157137 Korean.
Cited by
-
Effectiveness of Helicobacter pylori eradication in the treatment of early-stage gastric mucosa-associated lymphoid tissue lymphoma: An up-to-date meta-analysis.World J Gastroenterol. 2023 Apr 14;29(14):2202-2221. doi: 10.3748/wjg.v29.i14.2202. World J Gastroenterol. 2023. PMID: 37122607 Free PMC article.
-
Research on Key Technologies of Microarray Chips for Detecting Drug-Resistant Genes in Helicobacter pylori.Micromachines (Basel). 2024 Mar 21;15(3):416. doi: 10.3390/mi15030416. Micromachines (Basel). 2024. PMID: 38542663 Free PMC article.
-
Helicobacter pylori infection in gastric mucosa-associated lymphoid tissue lymphoma.World J Gastroenterol. 2014 Mar 21;20(11):2751-9. doi: 10.3748/wjg.v20.i11.2751. World J Gastroenterol. 2014. PMID: 24659867 Free PMC article. Review.
-
Helicobacter pylori Eradication Therapy Is Effective as the Initial Treatment for Patients with H. pylori-Negative and Disseminated Gastric Mucosa-Associated Lymphoid Tissue Lymphoma.Gut Liver. 2016 Sep 15;10(5):706-13. doi: 10.5009/gnl15510. Gut Liver. 2016. PMID: 27114423 Free PMC article.
-
Endoscopic features aiding the diagnosis of gastric mucosa-associated lymphoid tissue lymphoma.Yeungnam Univ J Med. 2019 May;36(2):85-91. doi: 10.12701/yujm.2019.00136. Epub 2019 Feb 26. Yeungnam Univ J Med. 2019. PMID: 31620618 Free PMC article. Review.
References
-
- Brooks JJ, Enterline HT. Primary gastric lymphomas. A clinicopathologic study of 58 cases with long-term follow-up and literature review. Cancer. 1983;51:701–711. - PubMed
-
- Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer. 1972;29:252–260. - PubMed
-
- Lim FE, Hartman AS, Tan EG, Cady B, Meissner WA. Factors in the prognosis of gastric lymphoma. Cancer. 1977;39:1715–1720. - PubMed
-
- Sandler RS. Has primary gastric lymphoma become more common? J Clin Gastroenterol. 1984;6:101–107. - PubMed
-
- Severson RK, Davis S. Increasing incidence of primary gastric lymphoma. Cancer. 1990;66:1283–1287. - PubMed
LinkOut - more resources
Full Text Sources